Advanced glycation end products (AGE) and diabetes: Cause, effect, or both?

Current Diabetes Reports

Volumn 14, Issue 1, 2014, Pages

  Vlassara, Helen ^a   Uribarri, Jaime ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

AGE receptors; AGER1; Diet; Glycation; Inflammation; Innate immunity; Oxidation; SIRT1

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

AGE; ARTICLE; CHRONIC INFLAMMATION; DEFENSE MECHANISM; DIABETES MELLITUS; GASTROINTESTINAL ABSORPTION; HUMAN; HYPERGLYCEMIA; INNATE IMMUNITY; LIFESTYLE MODIFICATION; NONHUMAN; NUTRITION; OBESITY; OXIDATIVE STRESS; FEMALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY; PREGNANCY DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; GLYCATION END PRODUCTS, ADVANCED; HUMANS; PREGNANCY;

MLCS; MLOWN;

EID: 84896736034     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0453-1     Document Type: Article

References (74)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14 Suppl 5:S1-S85.
2. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE. Diabetes and advanced glycoxidation end products. Diabetes Care. 2006;29:1420-32.
3. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 2004;27:2444-9.
4. No authors listed. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86.
5. No authors listed. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65.
6. Skyler JS et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53:298-304.
7. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse III JR, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
8. Duckworth W et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
10. Vlassara H, Palace MR. Diabetes and advanced glycation end products. J Intern Med. 2002;251:87-101.
11. Thorpe SR, Baynes JW. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging. 1996;9:69-77.
12. Beyan H, Riese H, Hawa MI, Beretta G, Davidson HW, Hutton JC, et al. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes. 2012;61:1192-8.
13. Zhao Z, Zhao C, Zhang XH, Zheng F, Cai W, Vlassara H, et al. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology. 2009;150:2569-76.
14. Peppa M, He C, Hattori M, McEvoy R, Zheng F, Vlassara H. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes. 2003;52:1441-8.
15. Hofmann SM, Dong HJ, Li Z, Cai W, Altomonte J, Thung SN, et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes. 2002;51:2082-9.
16. Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes. 2005;54:2314-9.
17. Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol. 2008;173:327-36.
18. Cai W, He JC, Zhu L, Chen X, Wallenstein S, Striker GE, et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol. 2007;170:1893-902.
19. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, et al. Circulating glycotoxins and dietary advanced glycation end products: two links to inflammatory response, oxidative stress and aging. J Gerontol Med Sci. 2007;62:427-33.
20. Suarez G, Rajaram R, Oronsky AL, Gawinowicz MA. Nonenzymatic glycation of bovine serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by glucose. J Biol Chem. 1989;264:3674-9.
21. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low-density lipoprotein receptor. J Biol Chem. 1995;270:10828-32.
22. Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Zhu L, et al. Protection against loss of innate defenses in adulthood by low AGE intake: role of a new anti-inflammatory AGE-receptor-1. J Clin Endocrinol Metab. 2009;94:4483-91.
23. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Bueting C, et al. Orally absorbed reactive advanced glycation end products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94:6474-9.
24. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A. 1997;94:13915-20.
25. O'Brien J, Morrissey PA. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr. 1989;28:211-48.
26. Cai W, Gao Q-D, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8:337-46.
27. Van Boekel MA. Formation of flavour compounds in the Maillard reaction. Biotechnol Adv. 2006;24:230-3.
28. He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes. 1999;48:1308-15.
29. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110:911-6. This review includes an extensive database with the AGE content of many foods allowing the practical implementation of an AGE-restricted diet.
30. Goldberg T, Cai W, Peppa M, Dardaine V, Uribarri J, Vlassara H. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104:1287-91.
31. Mericq V, Piccardo C, Cai W, Chen X, Zhu L, Striker GE, et al. Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care. 2010;33:2232-7.
32. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation end products (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A. 2012;109:15888-93. This study in mice documented very well the mechanisms by which AGEs induce insulin resistance and demonstrated that successive generations of animals chronically exposed to high AGE diets develop insulin resistance at a progressively earlier age.
33. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011;34:1610-6. This clinical trial documented for the first time that insulin resistance in humans can be reversed by an AGE-restricted diet.
34. Tajiri Y, Moller C, Grill V. Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. Endocrinology. 1997;138:273-8.
35. Tajiri Y, Grill V. Aminoguanidine exerts a beta-cell function-preserving effect in high glucose-cultured beta cells (INS-1). Int J Exp Diabetes Res. 2000;1:111-9.
36. Coughlan MT, Yap FY, Tong DC, Andrikopoulos S, Gasser A, Thallas-Bonke V, et al. Advanced glycation end products are direct modulators of β-cell function. Diabetes. 2011;60:2523-32.
37. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596-601.
38. Nicholl ID, Stiit AW, Moore JE, Ritchie AJ, Archer DB, Bucala R. Increased levels of advanced glycation end products in the lenses and blood vessels of cigarette smokers. Mol Med. 1998;4:594-601.
39. Cai W, He C, Zhu L, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A. 2006;103:13801-6.
40. Cai W, Torreggiani M, Zhu L, Chen X, He JC, Striker GE, et al. AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am J Physiol Cell Physiol. 2010;298:C624-32.
41. Lu H, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation end product (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A. 2004;101:11767-72.
42. Torreggiani M, Liu H, Wu J, Zheng F, Cai W, Striker G, et al. Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol. 2009;175:1722-32.
43. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycatione end products. J Mol Med. 2005;83:876-86.
44. Lukic IK, Humpert PM, Nawroth PP, Bierhaus A. The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann N Y Acad Sci. 2008;1126:76-80.
45. Saito A, Nagai R, Tanuma A, Hama H, Cho K, Takeda T, et al. Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. J Am Soc Nephrol. 2003;14:1123-31.
46. Vlassara H, Torreggiani M, Post JB, Zheng F, Uribarri J, Striker GE. Role of oxidants/inflammation in declining renal function in chronic kidney diseases and normal aging. Kidney Int. 2009;114(Suppl):S3-S11.
47. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836-42.
48. Odetti P, Traverso N, Cosso L, Noberasco G, Pronzato MA, Marinari UM. Good glycemic control reduces oxidation and glycation end-products in collagen of diabetic rats. Diabetologia. 1996;39:1440-7.
49. Vlassara H, Striker GE. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep. 2007;7:235-41.
50. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457-68.
51. Yoshida S, Yamada K, Hamaguchi K, Nishimura M, Hatakeyama E, Tsuchida H, et al. Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol. 1998;49:273-80.
52. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, et al. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis. 1999;142:67-77.
53. Stitt AW, He C, Friedman S, Scher L, Rossi P, Ong L, et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med. 1997;3:617-27.
54. Yoshida N, Okumura K, Aso Y. High serum pentosidien concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism. 2005;54:345-50.
55. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, et al. Increased serum levels of advanced glycation end products predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia. 2007;50:1409-17.
56. Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care. 2007;30:2579-82.
57. Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Götting C, et al. Effects of low- and high-advanced glycation end product meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2007;85:1236-43.
58. Uribarri J, Peppa M, Goldberg T, Cai W, Lu M, He C, et al. Restriction of dietary glycotoxins markedly reduces elevated advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14:728-31.
59. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int. 1996;50:627-34.
60. Panagiotopoulos S, O'Brien RC, Bucala R, Cooper ME, Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis. 1998;136:125-31.
61. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol. 2001;12:2098-107.
62. Voziyan PA, Hudson BG. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci. 2005;1043:807-16.
63. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27:605-14.
64. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes. 1997;46:895-9.
65. Wada R, Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest. 2001;31:513-20.
66. Odetti P, Robaudo C, Valentini S, Gurreri G, Garibaldi S, Angeletti S, et al. Effect of a new vitamin E-coated membrane on glycoxidation during hemodialysis. Contrib Nephrol. 1999;127:192-9.
67. Nakayama M, Izumi G, Nemoto Y, Shibata K, Hasegawa T, Numata M, et al. Suppression of N(epsilon)-(carboxymethyl)lysine generation by the antioxidant N-acetylcysteine. Perit Dial Int. 1999;19:207-10.
68. Trachtman H, Futterweit S, Prenner J, Hanon S. Antioxidants reverse the antiproliferative effect of high glucose and advanced glycosylation end products in cultured rat mesangial cells. Biochem Biophys Res Commun. 1994;199:346-52.
69. Kunt T, Forst T, Wihelm A, Rtitschler H, Pfuentzner A, Harzer O, et al. Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Clin Sci. 1999;96:75-82.
70. Jakus V, Hrnclarova M, Carsky J, Krahulec B, Rietbrock N. Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with antioxidant activity. Life Sci. 1999;65:1991-3.
71. Hammes HP, Bartmann A, Engel L, Wulfroth P. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia. 1997;40:629-34.
72. Vlassara H. AGEs as a preventable cause of diabetes and its complications. Diabetolo Chron. 2011;24(3):155-60.
73. Vlassara H, Striker G. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7:526-39.
74. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7:934-42. This clinical trial in patients with diabetic nephropathy demonstrates that an oral resin, sevelamer carbonate, used clinically to control hyperphosphatemia is also effective in reducing circulating AGEs and markers of inflammation and oxidative stress in this population.